Timing of Alzheimer's disease biomarker progressions: A two‐decade observational study from the Alzheimer's Disease Neuroimaging Initiative (ADNI)
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.14306 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Tamar Schaap und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterans Affairs Medical Center, Northern California Institute for Research and Education (NCIRE), San Francisco, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Disease Progression, Positron-Emission Tomography. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Alzheimer's Disease Neuroimaging Initiative (ADNI) has been pivotal in identifying and refining Alzheimer's disease (AD) biomarkers for clinical trials. This study leverages longitudinal data from participants who have progressed to amyloid‐positivity during their study participation to track evolution of biomarkers and cognitive function. METHODS We modeled AD biomarker (positron emission tomography [PET], structural, cerebrospinal fluid [CSF], cognition) trajectories before and after observed amyloid‐positivity onset time to detect time at which each biomarker had detectable trajectory changes. RESULTS Analysis of a sub‐cohort of the 20‐year ADNI study ( N = 90) recapitulated Alzheimer's progression beginning with amyloid alterations ‐4.8 to ‐5.3 years relative to amyloid‐positivity, succeeded by neurodegeneration (t = ‐4.0 to ‐4.1 years), and CSF tau (t = ‐0.4 to ‐0.5 years). Cognitive decline was observed to significantly correspond with emergence of amyloid‐positivity (t = 0.2 to 2.4 years). DISCUSSION Our results corroborate temporal progression curves of AD biomarkers, providing insights on earliest detectable changes in objective and subjective cognitive function assessments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterans Affairs Medical Center, Northern California Institute for Research and Education (NCIRE), San Francisco, California, USA.
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Pamela Thropp, Duygu Tosun
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Schaap, T., Thropp, P., Tosun, D., & Alzheimer's Disease Neuroimaging Initiative (2024). Timing of Alzheimer's disease biomarker progressions: A two‐decade observational study from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's & Dementia. https://doi.org/10.1002/alz.14306
Vancouver
Schaap T, Thropp P, Tosun D, Alzheimer's Disease Neuroimaging Initiative. Timing of Alzheimer's disease biomarker progressions: A two‐decade observational study from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's & Dementia. 2024. doi:10.1002/alz.14306
BibTeX
@article{Schaap2024,
author = {Schaap, Tamar and Thropp, Pamela and Tosun, Duygu and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
title = {Timing of Alzheimer's disease biomarker progressions: A two‐decade observational study from the Alzheimer's Disease Neuroimaging Initiative (ADNI)},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.14306}
}
EUVIMED